Technology | July 13, 2012

First Successful Below-The-Knee Angioslide Embolic Capture Performed in U.S.

The new 3x100 mm, low-profile Proteus device successfully captured and removed embolic material in below-the-knee interventions

July 13, 2012 — Angioslide Ltd., a provider of embolic capture angioplasty solutions, today announced the successful deployment of a 3x100 mm Proteus device for treating peripheral artery disease (PAD) in below-the-knee (BTK) vasculature at Community Hospital in Munster, Ind. Accommodating a 0.014 inch guide-wire, the new device allows physician to perform a percutaneous transluminal angioplasty (PTA) revascularization in BTK vessels while capturing and removing embolic particles.

Angioslide’s proprietary technology combines the functionality of a balloon angioplasty device with the addition of capture and removal of particles released during intervention.  Capture of embolic material is enabled by the inward folding of the balloon through a dedicated handle, which creates a suction effect that pulls embolic material into the cavity.  When retrieved through the sheath, Proteus removes the captured material from the body.

The Proteus device addresses an unmet need for an easy-to-use, efficient and cost-effective embolic removal solution for the peripheral vascular disease market. It is the first device of its kind to receive U.S. Food and Drug Administration (FDA) clearance for use in lower limbs (the femoral, iliac, ilio-femoral, popliteal, tibial, peroneal, and profunda arteries). The device has also received European CE mark approval for lower limb use and is being marketed in selected regions in Europe. Angioslide headquarters are located in Caesarea, Israel, and Denver Colo.

For more information: www.angioslide.com

 

 


Related Content

Feature | Cath Lab | Kyle Hardner

Since receiving FDA approval in 2016, intravascular lithotripsy (IVL) systems have grown in popularity among ...

Home November 14, 2025
Home
News | Cath Lab

Nov. 11, 2025 — FastWave Medical has successfully completed enrollment in its 30-patient coronary feasibility study and ...

Home November 13, 2025
Home
News | Cath Lab

Oct. 28, 2025 — Results from the first-of-its-kind randomized PROCTOR trial found that a strategy of saphenous vein ...

Home November 04, 2025
Home
News | Cath Lab

Oct. 27, 2025 — Results from the PREVUE-VALVE study suggest that there are currently at least 4.7 million people aged 65 ...

Home October 29, 2025
Home
News | Cath Lab

Oct. 25, 2025 — Medtronic plc has announced the launch of the Stedi Extra Support guidewire, designed to enhance ...

Home October 28, 2025
Home
News | Cath Lab

Oct. 27, 2025 — Elixir Medical, a developer of technologies to treat cardiovascular disease, has announced new clinical ...

Home October 28, 2025
Home
News | Cath Lab

Oct. 22, 2025 — Heartflow, Inc. has introduced Heartflow PCI Navigator, the newest addition to the Heartflow One ...

Home October 23, 2025
Home
News | Cath Lab

Oct. 15, 2025 — Stereotaxis recently announced it has obtained CE Mark in Europe and submitted a 510(k) application to ...

Home October 16, 2025
Home
News | Cath Lab

Oct. 7, 2025 — Medtronic has announced the full distribution of the Neuroguard IEP System (Neuroguard) after a ...

Home October 07, 2025
Home
News | Cath Lab

Sept. 22, 2025 — Nicklaus Children's Heart Institute in Miami, Florida, is now offering bedside transcatheter patent ...

Home September 23, 2025
Home
Subscribe Now